Heron Therapeutics (HRTX) Tops Q1 EPS by 1c

Heron Therapeutics (NASDAQ: HRTX) reported Q1 EPS of ($0.27), $0.01 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $29.62 million versus the consensus estimate of $30.84 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• B.C. households cutting back on groceries and essentials as cost-of-living crisis worsens: new survey